April 15th, 2025
Coronavirus Updates - Page 3
Pfizer (PFE) Vaccine Now Administered in UK, First Person Gets Vaccine Outside Trial
By Godfrey Benjamin
December 8th, 2020
While the Pfizer (PFE) vaccine is the first of the vaccines expected to get regulatory approval this year, its distribution may be limited considering its extremely low storage and distribution temperature of minus 70 degrees Celsius and below.
Former Democratic Congressman Proposes $1500 Stimulus Check for COVID-19 Vaccination
By John K. Kumi
December 4th, 2020
All that matters is to have the majority willing to get the vaccine, and once 75% of the population is immune, the minority who did not get vaccinated would be safe.
Alibaba-Backed Cainiao and Ethiopian Airlines to Export China’s COVID-19 Vaccines
By Steve Muchoki
December 3rd, 2020
According to the details provided by Cainiao, the shipments are expected to be delivered globally within 72 hours to ensure efficiency.
Adobe: 2020 Black Friday Online Shopping to Hit Record Sales as Shoppers Skip Stores
By Bhushan Akolkar
November 28th, 2020
The stricter social distancing norms and COVID-19 restrictions have pushed shoppers to turn online this holiday season. Adobe is expecting the biggest single-day sales ever in history during Cyber Monday.
Dow Jones Slips Below 30,000 Levels on Rising Jobless Claims
By Bhushan Akolkar
November 26th, 2020
Markets remained under pressure on Wednesday after the freshly released data showed an unexpected jump in the jobless claims. The rising COVID-19 cases put a curtain on the future of the economic recovery with possible signs of a delayed comeback.
Merck Seals $425M Buyout Deal with OncoImmune for COVID-19 Drug
By Godfrey Benjamin
November 23rd, 2020
The deal with OncoImmune will see Merck take up the ownership of CD24Fc with additional payment made to OncoImmune based on future favorable regulatory approvals associated with the drug.
REGN Stock Up 5% in Pre-market, Regeneron COVID-19 Drug Approved for Emergency Use by FDA
By Steve Muchoki
November 23rd, 2020
Regeneron noted that the initial dose of its COVID-19 drug will be released through a federal government allocation program to approximately 300,000 patients across the country.
AstraZeneca Vaccine Shows Efficacy of Up to 90%
By John K. Kumi
November 23rd, 2020
One of the regimens came out with 62% efficacy when administered for one month apart in two full doses. The other dosing regimen came out with an efficacy rate of 90% when administered for at least a month apart with a half dose followed by a full dose.
Pfizer and BioNTech File for EUA with FDA for Their COVID-19 Vaccine
By Godfrey Benjamin
November 20th, 2020
Pfizer is on track to deliver up to 50 million doses in 2020 and about 1.3 billion doses in 2021.
Hungary and Poland Veto EU Coronavirus Stimulus Deal
By Godfrey Benjamin
November 18th, 2020
European nations Hungary and Poland are reportedly bringing a setback to the European Commission as both countries have decided to veto the coronavirus stimulus deal agreed on by the commission.
PFE Stock Down 2% Now, Pfizer Launches COVID-19 Vaccine Delivery Trial in US
By Godfrey Benjamin
November 17th, 2020
Pfizer noted that the decision to conduct the vaccine delivery trial was based on the uniqueness of each state because of their size, existing immunization infrastructure, diversity in the population and other factors.
MRNA Stock Up 14% in Pre-Market as Moderna COVID-19 Vaccine Hits 94.5% Efficacy
By Godfrey Benjamin
November 16th, 2020
The Moderna vaccine trial involved about 30,000 participants and the interim analysis for the vaccine was based on 95 infections among the trial participants
Second Stimulus Package for Americans May Be Delayed
By Steve Muchoki
November 16th, 2020
JPMorgan chief US economist expects an around $1 trillion stimulus package early next year. However, Goldman Sachs analysts expect a $1 trillion stimulus package before the end of the year.
JNJ Stock Slightly Up as Johnson & Johnson Covid-19 Vaccine Enters Late Stage Trials
By Steve Muchoki
November 16th, 2020
If the company’s vaccine proves its efficacy, JNJ stocks are poised to significantly benefit from it and are likely to experience much higher volatility.
Dow Jones Drops 300 Points on Fears of Slow Economic Growth with Increase of COVID-19 Cases
By Bhushan Akolkar
November 13th, 2020
The path to economic recovery looks bleak, delayed, and uncertain at this point as the daily COVID-19 cases continue to hit a record high in the US. Even the latest positive vaccine news has failed to hold up the market.